Step by Step


ABIM MOC Activity ID

12/15/2020 - MGR: Bench to Bedside: Data-Driven Approaches to Resolving the Heterogeneity of Heart Failure with Preserved Ejection Fraction and HFpEF and the hemodynamics of heart failure?





Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Recognize the role of obesity in the pathophysiology of HFpEF.
  • Delineate methods for classifying complex clinical syndromes using data-driven approaches
  • Improve understanding and recognition of HFpEF subphenotypes
  • List the causes of a low BNP in patients with HFpEF
  • Describe the role of the gut in patients with HFpEF and right-sided heart failure
  • Describe the potential utility of left atrial unloading in patients with HFpEF and left atrial myopathy
  • Describe the evaluation of HFpEF
  • Discuss the hemodynamic phenotypes of HFpEF

Suggested Additional Reading & Joint Accreditation Statement: Note: This Accreditation Statement Supersedes All Other Statements:

Suggested additional reading:

  1. Circulation. 2018 Aug 28;138(9):861-870. doi: 10.1161/CIRCULATIONAHA.118.034646.
  2. Eur Heart J. 2018 Aug 7;39(30):2810-2821. doi: 10.1093/eurheartj/ehy268.
  3. Eur Heart J. 2018 Aug 7;39(30):2825-2835. doi: 10.1093/eurheartj/ehy331.
  4. J Am Coll Cardiol. 2020 Sep 1;76(9):1051-1064. doi: 10.1016/j.jacc.2020.07.009.
  5. Eur Heart J. 2020 Nov 23:ehaa823. doi: 10.1093/eurheartj/ehaa823. 
  6. Sanders-van Wijk S…Shah SJ. Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure With Preserved Ejection Fraction: Results From the PROMIS-HFpEF Study. Circulation. 2020;142(21):2029-2044.
  7. Shah SJ, et al. Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary. Circulation. 2020;141(12):1001-1026.
  8. Shah SJ, et al. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation. 2015;131(3):269-79.

Joint Providership Statement: 
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Pittsburgh School of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit[s]™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This educational activity is approved for 1.0 contact hours.

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

Barry Borlaug, MD — Professor of Medicine Director, Circulatory Failure Research, Division of Cardiovascular Diseases Chair for Research, Division of Circulatory Failure, Department of Cardiovascular Medicine Mayo Clinic, Rochester, Minnesota
Dr. Borlaug receives grant/research support from NIH/NHLBI, AstraZeneca, Corvia, Medtronic, GlaxoSmithKline, Tenax, and Mesoblast. He is a consultant for Johnson & Johnson, Aria, Merk, Novartis, Eli Lilly and Novo Nordisk.
Sanjiv Shah, MD — Director, Institute for Augmented Intelligence in Medicine – Center for Deep Phenotyping and Precision Therapeutics Director, Northwestern Heart Failure with Preserved Ejection Fraction Program Stone Endowed Professor of Medicine (Cardiology) Northwestern University Feinberg School of Medicine
Dr. Shah receives grant/research support from Actelion, AstraZeneca, Pfizer, Novartis and Corvia. He is a consultant with Lilly Medical, Novo Nordisk, Amgen, Aria CV, Axon, Bayer, Bristol Myers Squib, Boehringer-Ingelheim, Cardiora, Cyclerion, Cytokinetics, Eisai, GSK, Imara, Ionis, Ironwood, Keyto, Merck, MyoKardia, Regeneron, Sanofi, Shifamed, United Therapeutics, Boston Scientific, Abbott, CVRx,, Janssen, Prothena, Tenax, Actelion, AstraZeneca, Pfizer, and Novartis.
No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The University of Pittsburgh is an affirmative action, equal opportunity institution.